Claims for Patent: 6,083,725

Summary for Patent: 6,083,725

Title:	Tranfected human cells expressing human .alpha.-galactosidase A protein
Abstract:	A therepeutic method whereby an individual suspected of having an .alpha.-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human .alpha.-gal A, or (2) purified human .alpha.-gal A obtained from cultured, genetically modified human cells.
Inventor(s):	Selden; Richard F. (Wellesley, MA), Borowski; Marianne (Winthrop, MA), Gillispie; Frances P. (Lexington, MA), Kinoshita; Carol M. (Bedford, MA), Treco; Douglas A. (Arlington, MA), Williams; Melanie D. (Natick, MA)
Assignee:	Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:	08/928,881
Patent Claims:	1. A DNA molecule comprising a first sequence encoding the hGH signal peptide (SEQ ID NO:21), said first sequence comprising an intron; and, linked to the 3' end of the first sequence, a second sequence encoding a polypeptide comprising human .alpha.-gal A. 2. The DNA molecule of claim 1, further comprising a 3' untranslated sequence comprising a polyadenylation site. 3. An expression construct comprising the DNA molecule of claim 1 and suitable for expression in a human cell. 4. A cultured human cell containing a DNA molecule that (a) encodes a polypeptide comprising human .alpha.-gal A linked to an heterologous signal peptide, and (b) permits expression of the polypeptide in the cell. 5. The cell of claim 4, said cell being a fibroblast. 6. The cell of claim 4, wherein said cell is selected from the group consisting of an epithelial cell, an endothelial cell, a bone marrow cell, a glial cell, a hepatocyte, a keratinocyte, a myocyte, a neuron, or a precursor of these cell types. 7. The cell of claim 4, wherein said signal peptide is the hGH signal peptide (SEQ ID NO:21). 8. The cultured human cell of claim 4, wherein the DNA is introduced into the cell, or a precursor of the cell, by liposome-mediated transfection, polybrene-mediated transfection, DEAE dextran-mediated transfection, electroporation, calcium phosphate precipitation, microinjection, or velocity driven microprojectiles. 9. A clonal cell strain of cultured human cells transfected with a DNA molecule that (a) encodes a polypeptide comprising human .alpha.-gal A linked to an heterologous signal peptide, and (b) permits expression of the polypeptide in the cells. 10. The clonal cell strain of claim 9, said cells being fibroblasts. 11. The clonal cell strain of claim 9, wherein the strain is descended from a cell that was transfected with the DNA molecule by liposome-mediated transfection, polybrene-mediated transfection, DEAE dextran-mediated transtection, electroporation, calcium phosphate precipitation, microinjection, or velocity driven microprojectiles. 12. A clonal cell line of immortalized human cells transfected with a DNA molecule that (a) encodes a polypeptide comprising human .alpha.-gal A linked to an heterologous signal peptide, and (b) permits expression of the polypeptide in the cells. 13. The clonal cell line of claim 12, wherein said cells are selected from the group consisting of Bowes melanoma cells, Daudi cells, HeLa cells, HL-60 cells, HT1080 cells, Jurkat cells, KB carcinoma cells, K-562 leukemia cells, MCF-7 breast cancer cells, MOLT-4 cells, Namalwa cells, Raji cells, RPMI 8226 cells, U-937 cells, WI-38VA13 (subline 2R4) cells, and 2780AD ovarian carcinoma cells. 14. The clonal cell line of claim 12, wherein the cell line is descended from a cell that was transfected with the DNA molecule by liposome-mediated transfection, polybrene-mediated transfection, DEAE dextran-mediated transfection, electroporation, calcium phosphate precipitation, microinjection, or velocity driven microprojectiles. 15. A protein comprising (a) the hGH signal peptide (SEQ ID NO:21) linked by a peptide bond to (b) human .alpha.-gal A. 16. A process for making glycosylated human .alpha.-gal A, comprising culturing the cell of claim 5, under conditions permitting expression of human .alpha.-gal A from said DNA molecule and secretion of glycosylated human .alpha.-gal A into the culture medium of the cell; and isolating glycosylated human .alpha.-gal A from the culture medium. 17. A process for making glycosylated human .alpha.-gal A, comprising culturing the cell of claim 12 under conditions permitting expression of human .alpha.-gal A from said DNA molecule and secretion of glycosylated human .alpha.-gal A into the culture medium of the cell; and isolating glycosylated human .alpha.-gal A from the culture medium. 18. A method for making glycosylated human .alpha.-gal A, comprising culturing a human cell containing a DNA molecule that encodes a polypeptide comprising human .alpha.-gal A and a heterologous signal peptide under conditions permitting expression of human .alpha.-gal A from said DNA molecule. 19. The cell of claim 4, wherein said cell is an epithelial cell. 20. The cell of claim 4, wherein said cell is a bone marrow cell. 21. The cell of claim 4, wherein said cell is a keratinocyte. 22. The cell of claim 4, wherein said cell is a myocyte. 23. The clonal cell line of claim 12, wherein said cells are Ht1080 cells. 24. The clonal cell line of claim 12, wherein said cells are K-562 leukemia cells. 25. The clonal cell line of claim 12, wherein said cells are U-937 cells. 26. The cultured human cell of claim 4, wherein the DNA is introduced into the cell, or a precursor of the cell, by liposome-mediated transfection. 27. The cultured human cell of claim 4, wherein the DNA is introduced into the cell, or a precursor of the cell, by electroporation. 28. The cultured human cell of claim 4, wherein the DNA is introduced into the cell, or a precursor of the cell, by calcium phosphate precipitation. 29. The cultured human cell of claim 4, wherein the DNA is introduced into the cell, or a precursor of the cell, by microinjection. 30. The clonal cell strain of claim 9, wherein the strain is descended from a cell that was transfected with the DNA molecule by liposome-mediated transfection. 31. The clonal cell strain of claim 9, wherein the strain is descended from a cell that was transfected with the DNA molecule by electroporation. 32. The clonal cell strain of claim 9, wherein the strain is descended from a cell that was transfected with the DNA molecule by calcium phosphate precipitation. 33. The clonal cell strain of claim 9, wherein the strain is descended from a cell that was transfected with the DNA molecule by microinjection. 34. The clonal cell line of claim 12, wherein the cell line is descended from a cell that was transfected with the DNA molecule by liposome-mediated transfection. 35. The clonal cell line of claim 12, wherein the cell line is descended from a cell that was transfected with the DNA molecle by electroporation. 36. The clonal cell line of claim 12, wherein the cell line is descended from a cell that was transfected with the DNA molecule by calcium phosphate prescription. 37. The clonal cell line of claim 12, wherein the cell line is descended from a cell that was transfected with the DNA molecule by microinjection.

Details for Patent 6,083,725

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-09-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-09-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-09-13